Blacksmith Medicines Secures FDA QIDP and Fast Track Status for FG-2101, Advancing Critical Fight Against Drug-Resistant Gram-Negative Infections
In a significant milestone for antibiotic innovation, Blacksmith Medicines has been granted both Qualified Infectious Disease Product (QIDP) and Fast Track designations by the U.S. Food and Drug Administration (FDA) for its novel antibiotic candidate, FG-2101. This small molecule inhibitor targets LpxC, a metalloenzyme essential to the survival of Gram-negative bacteria, including multidrug-resistant strains—an area…
